Anti-CD20 Monoclonal Antibody 3,5,7

OCREVUS targets CD20-expressing B cells 4
Monoclonal anti-CD20 antibody

OCREVUS (ocrelizumab) is a recombinant humanized monoclonal antibody directed against CD20-expressing B cells. Lymphoid stem cells and plasma cells do not express CD20 and therefore are not directly targeted by OCREVUS.

The precise mechanisms through which OCREVUS exerts its therapeutic clinical effects in RMS and PPMS are not fully understood but are presumed to involve immunomodulation through selective binding to CD20-expressing B cells. Following cell surface binding to CD20-expressing B lymphocytes, OCREVUS is thought to trigger antibody-dependent cellular cytolysis and complement-mediated lysis.

OCREVUS use in numbers

See how OCREVUS use has grown since it began clinical trials to present day.

Request information

Speak to an OCREVUS Representative to learn more about OCREVUS.